Journal article · 2025 · Open access
POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE
Annals of the Rheumatic Diseases, 84, 366 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.05.454
In brief
“POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE” is a 2025 journal article by L. Bucci and 8 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 4 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 4
- Most cited in
- 2026 (3)
- Authors
- 9
Abstract
Background: Treatment of autoimmune disease with T cell engagers (TCEs) targeted against CD19 or BCMA leads to profound B cell depletion, followed by reconstitution [1, 2]. However, the dynamics of TCE activity in vivo, the dynamics of B cell depletion and reconstitution and the potential impacts on the endogenous T cell compartment in autoimmune disease are poorly understood. Objectives: To investigate the effects of TCE therapy on the B cell and T cell compartment in patients with different autoimmune diseases (AIDs), including rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), IgG4-related disease (IgG4-RD) and Grave's disease (GD). Methods: 14 patients with RA were treated in our department with the TCE CD19xCD3 Blinatumomab, 10 patients with various autoimmune diseases including SSc, IIM, IgG4-RD and GD were treated with the plasma cell-targeting TCE BCMAxCD3 teclistamab. Peripheral blood mononuclear cells (PBMCs) were isolated from each patient at baseline and regularly after the treatment. High dimensional flow cytometry was performed on PBMCs to quantify T and B cell phenotypes. 1-year follow-up was available for 8/14 patients treated with blinatumomab. 6-months follow-up was available for 5/10 patients treated with teclistamab. Results: Both blinatumomab and teclistamab lead to a rapid depletion of B cells in peripheral blood. 11/14 RA patients had circulating B cells at baseline (median 114/nl). In three patients, B cells were already peripherally depleted because of previous rituximab therapy (mean 3.3 months before blinatumomab [range: 3–4]). Blinatumomab lead to complete B cell depletion in 8 patients. B cell aplasia was reached after the first cycle in 2 patients and after the second cycle in 4 patients. 3/14 patients received a third cycle of blinatumomab, in 2 of them B cells were completely depleted after the third cycle. Further, 3 patients treated with blinatumomab did not have a complete B cell depletion. Teclistamab lead to complete B cell depletion in 10/10 patients. B cell aplasia was reached after the first teclistamab dose in 4/10 patients and in 6/10 patients after the third dose. B cells reconstituted after blinatumomab therapy after a median of 63 days (range 32-139) and after teclistamab after a median of 115 days (range 84-161). Reconstituted B cells were mostly of a naive B phenotype (mean value 84% in blinatumomab [range 66–90%], mean value 88% in teclistamab [range 85–96%]). Correspondingly, CD19 + CD27 + memory B cells decreased substantially, in blinatumomab from an average of 16%, [range 6.3–31%] to 7%, [range 0–16%] and in teclistamab from an average of 8% [range 2.6–18%], to 2%, [range 0.5–3.2%]. At one year…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bucci, L., Rothe, T., Anoshkin, K., Nöthling, D.-M., Götz, A., Eckstein, M., Raimondo, M. G., Schett, G. A., & Grieshaber‐Bouyer, R. (2025). POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases, 84, 366. https://doi.org/10.1016/j.ard.2025.05.454
MLA 9
Bucci, L., et al. “POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE.” Annals of the Rheumatic Diseases, vol. 84, 2025, p. 366. https://doi.org/10.1016/j.ard.2025.05.454.
Chicago
Bucci, L., Tobias Rothe, K. Anoshkin, Danae-Mona Nöthling, Alexandra Götz, Markus Eckstein, Maria Gabriella Raimondo, Georg Andreas Schett, and Ricardo Grieshaber‐Bouyer. 2025. “POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE.” Annals of the Rheumatic Diseases 84: 366. https://doi.org/10.1016/j.ard.2025.05.454.
Harvard
Bucci, L. et al. (2025) ‘POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE’, Annals of the Rheumatic Diseases, 84, p. 366. doi:10.1016/j.ard.2025.05.454.
IEEE
L. Bucci et al., “POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE,” Annals of the Rheumatic Diseases, vol. 84, p. 366, 2025, doi: 10.1016/j.ard.2025.05.454.
BibTeX
@article{bucci2025effects,
title = {{POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE}},
author = {Bucci, L. and Rothe, Tobias and Anoshkin, K. and Nöthling, Danae-Mona and Götz, Alexandra and Eckstein, Markus and Raimondo, Maria Gabriella and Schett, Georg Andreas and Grieshaber‐Bouyer, Ricardo},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {366},
doi = {10.1016/j.ard.2025.05.454},
url = {https://doi.org/10.1016/j.ard.2025.05.454}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- T-cell engagers
- CD19
- BCMA
- blinatumomab
- teclistamab
- B-cell depletion
- B-cell aplasia
- T cell depletion
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Bucci, L., Rothe, T., Anoshkin, K., Nöthling, D.-M., Götz, A., Eckstein, M., Raimondo, M. G., Schett, G. A., & Grieshaber‐Bouyer, R. (2025). POS0057 EFFECTS OF T CELL ENGAGERS TREATMENT ON B AND T CELLS IN AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases, 84, 366. https://doi.org/10.1016/j.ard.2025.05.454
How many times has this paper been cited?
4 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
L. Bucci, Tobias Rothe, K. Anoshkin, Danae-Mona Nöthling, Alexandra Götz, Markus Eckstein, Maria Gabriella Raimondo, Georg Andreas Schett, Ricardo Grieshaber‐Bouyer.
What is the DOI of this paper?
10.1016/j.ard.2025.05.454, permanently at https://doi.org/10.1016/j.ard.2025.05.454. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.